Puxitatug samrotecan (P-Sam), an investigational antibody-drug conjugate (ADC) targeting B7-H4-expressing tumors, showed promising efficacy in patients with advanced or metastatic endometrial ...

An Antibody-Drug Conjugate (ADC) comprises a drug linked to an anitbody. The anitbody binds selectively to cancer cells to deliver the drug into the cell.

GSK plc GSK announced that the FDA has granted a Breakthrough Therapy Designation to its investigational B7-H3-targeted antibody-drug conjugate (ADC), GSK5764227 (GSK’227), for the treatment of ...

The antibody-drug conjugate (ADC) field is advancing at an unprecedented pace, with groundbreaking innovations and soaring investment. A 33% rise in new drugs, a surge in clinical trials, and ...

Boehringer Ingelheim subsidiary NBE Therapeutics has opened its new antibody-drug conjugates (ADC) research and development (R&D) facility in Basel, Switzerland. The move aligns with Boehringer ...

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $1.03 per share a year ago. These ...

Jane Chung has replaced Bill Newell as Sutro's CEO. Antibody-drug conjugate (ADC) specialist Sutro Biopharma has shelved its lead drug for ovarian cancer and turned its attention to a trio of ...